Schaeffer's Top Stock Picks for '25

Drug Sales Surge Drives Regeneron Pharmaceuticals to Q2 Beat

Regeneron just reported a second-quarter earnings and revenue win

Digital Content Manager
Aug 3, 2023 at 10:40 AM
facebook X logo linkedin


Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported second-quarter revenue of $10.24 per share on revenue of $3.16 billion today, blowing past analysts' expectations. The company attributed the results to a 33% sales surge for its eczema drug Dupixent, and noted it expects the Food and Drug Administration (FDA) to approve a higher-dose version of eye disease drug Eylea in the third quarter.

Last seen up 5% at $768.51 at last check, the stock earlier moved above its 80-day moving average for the first time since late June. Overhead pressure at the $780 remains firmly in place, but over the past 12 months Regeneron Pharmaceuticals stock added 26.6%. 

Drilling down to today's options activity, 1,219 calls have been exchanged -- five times the intraday average volume -- compared to just 433 puts. The most popular is the weekly 8/25 780-strike call, followed by the weekly 8/11 780-stike call, with new positions being opened at both.
 
 

You have the chance to join one of Bernie's most exclusive programs, complete access at HUGE savings!

As we prepare for a new administration to take the reins in Washington, the near-term market landscape is rife with uncertainty.

The Federal Reserve has already hinted at the turbulence ahead, lowering its interest rate outlook for 2025.

Meanwhile, breakthroughs in artificial intelligence (AI), quantum computing, and other transformative sectors have unlocked incredible profit potential.

But these opportunities are fleeting, and timing is everything. That's where Quick-Hit Trader comes in.

Quick-Hit Trader is designed for precision and speed, getting you in and out of the market in a flash. While other investors scramble to navigate volatile conditions, you'll have access to expertly curated trades that leverage these rapid shifts to deliver explosive profits in short order.

This is your chance to capitalize on the fast-moving market like never before. Are you ready to make your move?